Igamad (Human Anti-D Immunoglobulin)

Human Anti-D Immunoglobulin binds to the RhD antigen on red blood cells, forming immune complexes that are cleared by the reticuloendothelial system. This prevents the mother's immune system from developing antibodies against Rh‑positive fetal cells and also modulates immune mechanisms that contribute to platelet destruction in ITP.

The dosage of Igamad is determined by the prescribing clinician based on the specific indication, patient weight, and clinical response. Healthcare professionals calculate the appropriate amount and schedule according to established guidelines and individual patient factors.

Igamad is administered to Rh‑negative pregnant women to prevent alloimmunization, a use that is generally considered safe when prescribed by a qualified obstetrician. Data on breastfeeding are limited; clinicians should weigh potential benefits against any unknown risks and advise patients accordingly.

To order Igamad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Igamad is comparable to other human anti‑D immunoglobulins in its mechanism of binding RhD antigen and preventing sensitisation. Differences may lie in manufacturing processes, purity levels, and regulatory approvals. Clinicians should consider product-specific data, availability, and institutional preferences when selecting an anti‑D therapy.

Igamad must be stored at 2‑8 °C in a refrigerator. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain is essential to preserve product stability and efficacy.

Igamad is supplied as an injectable solution for intramuscular injection. The healthcare professional selects an appropriate injection site, typically the deltoid or gluteal muscle, and follows aseptic technique. The exact volume and administration schedule are determined by the prescriber.

Serious risks include anaphylactic or severe allergic reactions, hemolysis, thrombotic events, renal impairment, and severe hypotension. Patients should be monitored closely during and after administration, and any signs of these reactions require immediate medical attention.

Igamad should be avoided in individuals with known hypersensitivity to human anti‑D immunoglobulin or any of its excipients, and in patients with documented IgA deficiency who have anti‑IgA antibodies. Caution is also advised for patients with severe cardiovascular disease or uncontrolled hypertension.